Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth

Journal of Immunology

Volumn 194, Issue 8, 2015, Pages 3542-3548

  Coulthard, Liam G ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA INTERFERON; CATHEPSIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR 2; COMPLEMENT INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN E2; SB 290157; THROMBIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; C3 PROTEIN, HUMAN; COMPLEMENT COMPONENT C3;

ADOPTIVE TRANSFER; ANTIINFLAMMATORY ACTIVITY; CALCIUM MOBILIZATION; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT C3 DEFICIENCY; COMPLEMENT DEFICIENCY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; DRUG RECEPTOR BINDING; ENCEPHALITIS; ENZYME ACTIVATION; ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MONOCYTE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; GENETICS; IMMUNOLOGY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY;

ANIMALS; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT C5A; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEUTROPHIL INFILTRATION; NEUTROPHILS;

EID: 84927592139     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403068     Document Type: Review

References (68)

1. Sjöberg, A. P., L. A. Trouw, and A. M. Blom. 2009. Complement activation and inhibition: a delicate balance. Trends Immunol. 30:83-90.
2. Mathieu, M.-C., N. Sawyer, G. M. Greig, M. Hamel, S. Kargman, Y. Ducharme, C. K. Lau, R. W. Friesen, G. P. O'Neill, F. G. Gervais, and A. G. Therien. 2005. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 100:139-145.
3. Proctor, L. M., T. V. Arumugam, I. Shiels, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2004. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 142:756-764.
4. Friedberger, E. 1909. Friedberger: Kritik der Theorien über die Anaphylaxie. Ztschr. Immunitätsforsch 2:208.
5. Friedberger, E., and T. Ito. 1911. Uber anaphylaxie: XXI Mitteilung. Naheres uber den mechanismus der komplementwirkung bei der anaphylatoxinbildung in vitro. Ztschr. Immunitätsforsch 11:471.
6. Dias Da Silva, W., and I. H. Lepow. 1967. Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J. Exp. Med. 125:921-946.
7. Cochrane, C. G., and H. J. Müller-Eberhard. 1968. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J. Exp. Med. 127:371-386.
8. Klos, A., E. Wende, K. J. Wareham, and P. N. Monk. 2013. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacol. Rev. 65:500-543.
9. Hugli, T. E. 1975. Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J. Biol. Chem. 250:8293-8301.
10. Markiewski, M. M., B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28:184-192.
11. Chazin, W. J., T. E. Hugli, and P. E. Wright. 1988. 1H NMR studies of human C3a anaphylatoxin in solution: sequential resonance assignments, secondary structure, and global fold. Biochemistry 27:9139-9148.
12. Hugli, T. E., and B. W. Erickson. 1977. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA 74:1826-1830.
13. Zipfel, P. F., and M. Reuter. 2009. Complement Activation Products C3a and C4a as Endogenous Antimicrobial Peptides. Int. J. Pept. Res. Ther. 15:87-95.
14. Lu, Z. X., K. F. Fok, B. W. Erickson, and T. E. Hugli. 1984. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide. J. Biol. Chem. 259:7367-7370.
15. Bellows-Peterson, M. L., H. K. Fung, C. A. Floudas, C. A. Kieslich, L. Zhang, D. Morikis, K. J. Wareham, P. N. Monk, O. A. Hawksworth, and T. M. Woodruff. 2012. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J. Med. Chem. 55:4159-4168.
16. Scully, C. C., J. S. Blakeney, R. Singh, H. N. Hoang, G. Abbenante, R. C. Reid, and D. P. Fairlie. 2010. Selective hexapeptide agonists and antagonists for human complement C3a receptor. J. Med. Chem. 53:4938-4948.
17. Kalant, D., S. A. Cain, M. Maslowska, A. D. Sniderman, K. Cianflone, and P. N. Monk. 2003. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 278:11123-11129.
18. Li, R., L. G. Coulthard, M. C. Wu, S. M. Taylor, and T. M. Woodruff. 2013. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27:855-864.
19. Kalant, D., R. MacLaren, W. Cui, R. Samanta, P. N. Monk, S. A. Laporte, and K. Cianflone. 2005. C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280:23936-23944.
20. Monsinjon, T., P. Gasque, P. Chan, A. Ischenko, J. J. Brady, and M. C. Fontaine. 2003. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17:1003-1014.
21. Sayah, S., A. C. Jauneau, C. Patte, M. C. Tonon, H. Vaudry, and M. Fontaine. 2003. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res. Mol. Brain Res. 112:53-60.
22. Shinjyo, N., A. Ståhlberg, M. Dragunow, M. Pekny, and M. Pekna. 2009. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 27:2824-2832.
23. Langkabel, P., J. Zwirner, and M. Oppermann. 1999. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by G proteincoupled receptor kinases. Eur. J. Immunol. 29:3035-3046.
24. Settmacher, B., D. Bock, H. Saad, S. Gärtner, C. Rheinheimer, J. Köhl, W. Bautsch, and A. Klos. 1999. Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a. J. Immunol. 162:7409-7416.
25. Hannedouche, S., V. Beck, J. Leighton-Davies, M. Beibel, G. Roma, E. J. Oakeley, V. Lannoy, J. Bernard, J. Hamon, S. Barbieri, et al. 2013. Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. J. Biol. Chem. 288:27434-27443.
26. Cero, C., V. V. Vostrikov, R. Verardi, C. Severini, T. Gopinath, P. D. Braun, M. F. Sassano, A. Gurney, B. L. Roth, L. Vulchanova, et al. 2014. The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanism. Structure 22:1744-1753.
27. Boos, L., I. L. Campbell, R. Ames, R. A. Wetsel, and S. R. Barnum. 2004. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 173:4708-4714.
28. Boos, L., A. J. Szalai, and S. R. Barnum. 2005. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci. Lett. 387:68-71.
29. Ruan, B. H., X. Li, A. R. Winkler, K. M. Cunningham, J. Kuai, R. M. Greco, K. H. Nocka, L. J. Fitz, J. F. Wright, D. D. Pittman, et al. 2010. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-a production in a receptor for advanced glycation end product-dependent manner. J. Immunol. 185:4213-4222.
30. Xie, J., J. D. Méndez, V. Méndez-Valenzuela, and M. M. Aguilar-Hernández. 2013. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25:2185-2197.
31. Klos, A., A. J. Tenner, K.-O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46:2753-2766.
32. Wu, M. C., F. H. Brennan, J. P. L. Lynch, S. Mantovani, S. Phipps, R. A. Wetsel, M. J. Ruitenberg, S. M. Taylor, and T. M. Woodruff. 2013. The receptor for complement component C3a mediates protection from intestinal ischemiareperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. USA 110:9439-9444.
33. Daffern, P. J., P. H. Pfeifer, J. A. Ember, and T. E. Hugli. 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119-2127.
34. Chen, N.-J., C. Mirtsos, D. Suh, Y.-C. Lu, W.-J. Lin, C. McKerlie, T. Lee, H. Baribault, H. Tian, and W.-C. Yeh. 2007. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446:203-207.
35. Takabayashi, T., E. Vannier, B. D. Clark, N. H. Margolis, C. A. Dinarello, J. F. Burke, and J. A. Gelfand. 1996. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J. Immunol. 156:3455-3460.
36. Takabayashi, T., E. Vannier, J. F. Burke, R. G. Tompkins, J. A. Gelfand, and B. D. Clark. 1998. Both C3a and C3a (desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J. Infect. Dis. 177:1622-1628.
37. Monsinjon, T., P. Gasque, A. Ischenko, and M. Fontaine. 2001. C3A binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. FEBS Lett. 487:339-346.
38. Fischer, W. H., M. A. Jagels, and T. E. Hugli. 1999. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a (desArg). J. Immunol. 162:453-459.
39. Asgari, E., G. Le Friec, H. Yamamoto, E. Perucha, S. S. Sacks, J. Köhl, H. T. Cook, and C. Kemper. 2013. C3a modulates IL-1b secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122:3473-3481.
40. Banda, N. K., S. Hyatt, A. H. Antonioli, J. T. White, M. Glogowska, K. Takahashi, T. J. Merkel, G. L. Stahl, S. Mueller-Ortiz, R. Wetsel, et al. 2012. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 188:1469-1478.
41. Fischer, W. H., and T. E. Hugli. 1997. Regulation of B cell functions by C3a and C3a (desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J. Immunol. 159:4279-4286.
42. Elsner, J., M. Oppermann, W. Czech, and A. Kapp. 1994. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83:3324-3331.
43. Takafuji, S., K. Tadokoro, K. Ito, and C. A. Dahinden. 1994. Degranulation from human eosinophils stimulated with C3a and C5a. Int. Arch. Allergy Immunol. 104 (1, Suppl. 1) 27-29.
44. Kubota, Y. 1992. The effect of human anaphylatoxins and neutrophils on histamine release from isolated human skin mast cells. J. Dermatol. 19:19-26.
45. Bautsch, W., H. G. Hoymann, Q. Zhang, I. Meier-Wiedenbach, U. Raschke, R. S. Ames, B. Sohns, N. Flemme, A. Meyer Zu Vilsendorf, M. Grove, et al. 2000. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J. Immunol. 165:5401-5405.
46. Lim, H., Y. U. Kim, S. M. Drouin, S. Mueller-Ortiz, K. Yun, E. Morschl, R. A. Wetsel, and Y. Chung. 2012. Negative regulation of pulmonary Th17 responses by C3a anaphylatoxin during allergic inflammation in mice. PLoS ONE 7:e52666.
47. + regulatory T cells. Nat. Immunol. 14:162-171.
48. Liszewski, M. K., M. Kolev, G. Le Friec, M. Leung, P. G. Bertram, A. F. Fara, M. Subias, M. C. Pickering, C. Drouet, S. Meri, et al. 2013. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39:1143-1157.
49. Martin, U., D. Bock, L. Arseniev, M. A. Tornetta, R. S. Ames, W. Bautsch, J. Köhl, A. Ganser, and A. Klos. 1997. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J. Exp. Med. 186:199-207.
50. + T cells. Immunity 28:425-435.
51. Kwan, W.-H., W. Van Der Touw, E. Paz-Artal, M. O. Li, and P. S. Heeger. 2013. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J. Exp. Med. 210:257-268.
52. Kawamoto, S., A. Yalcindag, D. Laouini, S. Brodeur, P. Bryce, B. Lu, A. A. Humbles, H. Oettgen, C. Gerard, and R. S. Geha. 2004. The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J. Clin. Invest. 114:399-407.
53. Drouin, S. M., D. B. Corry, T. J. Hollman, J. Kildsgaard, and R. A. Wetsel. 2002. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 169:5926-5933.
54. Kubes, P., J. Hunter, and D. N. Granger. 1992. Ischemia/reperfusion-induced feline intestinal dysfunction: importance of granulocyte recruitment. Gastroenterology 103:807-812.
55. Schofield, Z. V., T. M. Woodruff, R. Halai, M. C.-L. Wu, and M. A. Cooper. 2013. Neutrophils-a key component of ischemia-reperfusion injury. Shock 40:463-470.
56. Nakae, H., S. Endo, K. Inada, T. Takakuwa, T. Kasai, and M. Yoshida. 1994. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84:189-195.
57. Flierl, M. A., D. Rittirsch, B. A. Nadeau, D. E. Day, F. S. Zetoune, J. V. Sarma, M. S. Huber-Lang, and P. A. Ward. 2008. Functions of the complement components C3 and C5 during sepsis. FASEB J. 22:3483-3490.
58. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12:682-687.
59. Yuan, Y., J. Ren, X. Wu, S. Cao, and J. Li. 2011. Exogenous C3 postpones complement exhaustion and confers organ protection in murine sepsis. J. Surg. Res. 168:e87-e94.
60. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165:5406-5409.
61. Hollmann, T. J., S. L. Mueller-Ortiz, M. C. Braun, and R. A. Wetsel. 2008. Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a. Mol. Immunol. 45:1907-1915.
62. Mizuno, M., S. Blanchin, P. Gasque, K. Nishikawa, and S. Matsuo. 2007. High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am. J. Kidney Dis. 49:598-606.
63. Bao, L., I. Osawe, M. Haas, and R. J. Quigg. 2005. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J. Immunol. 175:1947-1955.
64. Wenderfer, S. E., H. Wang, B. Ke, R. A. Wetsel, and M. C. Braun. 2009. C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol. Immunol. 46:1397-1404.
65. Peng, Q., K. Li, L. A. Smyth, G. Xing, N. Wang, L. Meader, B. Lu, S. H. Sacks, and W. Zhou. 2012. C3a and C5a promote renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 23:1474-1485.
66. Tang, Z., B. Lu, E. Hatch, S. H. Sacks, and N. S. Sheerin. 2009. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J. Am. Soc. Nephrol. 20:593-603.
67. Proctor, L. M., T. A. Moore, P. N. Monk, S. D. Sanderson, S. M. Taylor, and T. M. Woodruff. 2009. Complement factors C3a and C5a have distinct hemodynamic effects in the rat. Int. Immunopharmacol. 9:800-806.
68. Halai, R., M. L. Bellows-Peterson, W. Branchett, J. Smadbeck, C. A. Kieslich, D. E. Croker, M. A. Cooper, D. Morikis, T. M. Woodruff, C. A. Floudas, and P. N. Monk. 2014. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. Eur. J. Pharmacol. 745:176-181.